The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study
Open accessAbstract
Among patients with von Willebrand disease (VWD) who are unresponsive to desmopressin therapy, replacement with plasma-derived concentrates is the treatment of choice. Because prospective studies are lacking, such treatment has been largely empirical. A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate for treatment of bleeding and surgical prophylaxis. Two preparations of the concentrate—one virally inactivated with solvent detergent, the other with an additional heat-treatment step—were evaluated. Pharmacokinetic parameters were similar for both preparations. Using pre-established dosages based on the results of pharmacokinetic studies, 53 patients were administered either preparation for the treatment of 87 bleeding episodes, and 39 patients were treated prophylactically for 71 surgical or invasive procedures. Sixty-five (74.7%) and 10 (11.5%) of the bleeding episodes were controlled with 1 or 2 infusions, respectively. Patients with severe type 3 VWD typically required more infusions and higher doses, at shorter time intervals, than did patients with generally milder types 1 and 2. Among patients undergoing surgical procedures, blood loss was lower than that predicted prospectively, and losses exceeding the predicted value did not correlate with the postinfusion skin bleeding time. In conclusion, the concentrate effectively stopped active bleeding and provided adequate hemostasis for surgical or invasive procedures, even in the absence of bleeding time correction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koster, T., Vandenbroucke, J. P., Rosendaal, F. R., Briët, E., Rosendaal, F. R., & Blann, A. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90166-3 · Cited by 1,131 · cited 6×
“2 or more infusions (range) 55 (55-55) 40 (14-50) 60 (19-79)”
Influential
Cited by
NICHOLS, W. L., HULTIN, M. B., JAMES, A. H., MANCO‐JOHNSON, M. J., MONTGOMERY, R. R., ORTEL, T. L., RICK, M. E., SADLER, J. E., WEINSTEIN, M., & YAWN, B. P. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2007.01643.x · Cited by 967
Treatment of von Willebrand's Disease
Mannucci, P. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040403 · Cited by 484
Self-citationInternational workshop on immune tolerance induction: consensus recommendations1
DIMICHELE, D. M., HOOTS, W. K., PIPE, S. W., RIVARD, G. E., & SANTAGOSTINO, E. (2007) · Haemophilia · doi:10.1111/j.1365-2516.2007.01497.x · Cited by 278
KEELING, D., TAIT, C., & MAKRIS, M. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01695.x · Cited by 258
Metadata
- Authors
- Mannucci, P. M., Chediak, J., Hanna, W., Byrnes, J., Ledford, M., Ewenstein, B. M., Retzios, A. D., Kapelan, B. A., Schwartz, R. S., Kessler, C., & the Alphanate Study Group
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-01-15
- Volume
- 99
- Issue
- 2
- Pages
- 450-456
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2044662855
- Cited by
- 193
- References
- 1
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. https://app.cochat.ai/papers/10.1182/blood.v99.2.450
- The paper
- Mannucci, P. M., Chediak, J., Hanna, W., Byrnes, J., Ledford, M., Ewenstein, B. M., Retzios, A. D., Kapelan, B. A., Schwartz, R. S., Kessler, C., & the Alphanate Study Group. (2002). Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. https://doi.org/10.1182/blood.v99.2.450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.